UPDATE - 2022 Canadian Urological Association recommendations on prostate cancer screening and early diagnosis Endorsement of the 2021 Cancer Care Ontario guidelines on prostate multiparametric magnetic resonance imaging.
作者信息
Mason Ross J, Marzouk Karim, Finelli Antonio, Saad Fred, So Alan I, Violette Philippe D, Breau Rodney H, Rendon Ricardo A
机构信息
Department of Urology, Dalhousie University, Halifax, NS, Canada.
Windsor General Hospital, Windsor, ON; and Western University, London, ON, Canada.
出版信息
Can Urol Assoc J. 2022 Apr;16(4):E184-E196. doi: 10.5489/cuaj.7851.
Abstract
摘要
相似文献
1
UPDATE - 2022 Canadian Urological Association recommendations on prostate cancer screening and early diagnosis Endorsement of the 2021 Cancer Care Ontario guidelines on prostate multiparametric magnetic resonance imaging.
Can Urol Assoc J. 2022 Apr;16(4):E184-E196. doi: 10.5489/cuaj.7851.
2
UPDATE - 2022 Canadian Urological Association recommendations on prostate cancer screening and early diagnosis Endorsement of the 2021 Cancer Care Ontario guidelines on prostate multiparametric magnetic resonance imaging - Summary of changes.
Can Urol Assoc J. 2022 Apr;16(4):86-87. doi: 10.5489/cuaj.7832.
3
Update of the Standard Operating Procedure on the Use of Multiparametric Magnetic Resonance Imaging for the Diagnosis, Staging and Management of Prostate Cancer.
J Urol. 2020 Apr;203(4):706-712. doi: 10.1097/JU.0000000000000617. Epub 2019 Oct 23.
4
Prostate-specific Antigen Testing as Part of a Risk-Adapted Early Detection Strategy for Prostate Cancer: European Association of Urology Position and Recommendations for 2021.
Eur Urol. 2021 Dec;80(6):703-711. doi: 10.1016/j.eururo.2021.07.024. Epub 2021 Aug 15.
5
Multiparametric Magnetic Resonance Imaging in Prostate Cancer Screening at the Age of 45 Years: Results from the First Screening Round of the PROBASE Trial.
Eur Urol. 2024 Feb;85(2):105-111. doi: 10.1016/j.eururo.2023.09.027. Epub 2023 Oct 18.
6
Diagnosis of prostate cancer: the implications and proper utilization of PSA and its variants; indications and use of MRI and biomarkers.
Can J Urol. 2020 Feb;27(27 Suppl 1):3-10.
7
Micro-Ultrasound-Guided vs Multiparametric Magnetic Resonance Imaging-Targeted Biopsy in the Detection of Prostate Cancer: A Systematic Review and Meta-Analysis.
J Urol. 2021 May;205(5):1254-1262. doi: 10.1097/JU.0000000000001639. Epub 2021 Feb 12.
8
EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer-2024 Update. Part I: Screening, Diagnosis, and Local Treatment with Curative Intent.
Eur Urol. 2024 Aug;86(2):148-163. doi: 10.1016/j.eururo.2024.03.027. Epub 2024 Apr 13.
9
Development and External Validation of a Multiparametric Magnetic Resonance Imaging and International Society of Urological Pathology Based Add-On Prediction Tool to Identify Prostate Cancer Candidates for Pelvic Lymph Node Dissection.
J Urol. 2020 Apr;203(4):713-718. doi: 10.1097/JU.0000000000000652. Epub 2019 Nov 13.
10
A Single Center Evaluation of the Diagnostic Accuracy of Multiparametric Magnetic Resonance Imaging against Transperineal Prostate Mapping Biopsy: An Analysis of Men with Benign Histology and Insignificant Cancer following Transrectal Ultrasound Biopsy.
J Urol. 2018 Aug;200(2):302-308. doi: 10.1016/j.juro.2018.02.072. Epub 2018 Mar 1.
引用本文的文献
1
Engaging for equity: Lessons from a cross-sector partnership addressing prostate cancer risk in the black community.
Res Involv Engagem. 2025 Jun 10;11(1):60. doi: 10.1186/s40900-025-00743-x.
2
A 10-year analysis of MRI-driven prostate cancer diagnosis and active surveillance: trends and implications.
BJU Int. 2025 Apr 14;136(2):224-6. doi: 10.1111/bju.16743.
3
Geographic, socioeconomic and demographic inequalities in the incidence of metastatic prostate cancer at time of diagnosis in England: a population-based evaluation.
BMJ Oncol. 2025 Apr 1;4(1):e000643. doi: 10.1136/bmjonc-2024-000643. eCollection 2025.
4
Assessing the methodologic heterogeneity of Canadian Urological Association guidelines Adoption of the GRADE approach (2018-2023).
Can Urol Assoc J. 2025 Jun;19(6):173-180. doi: 10.5489/cuaj.8926.
5
The rural disadvantage - prostate cancer outcomes of rural and urban patients over 25 years.
J Rural Health. 2025 Jan;41(1):e70008. doi: 10.1111/jrh.70008.
6
Cancer Screening and Cancer Treatment in Kidney Transplant Recipients.
Kidney360. 2024 Oct 1;5(10):1569-1583. doi: 10.34067/KID.0000000000000545.
7
Advanced Imaging for Localized Prostate Cancer.
Cancers (Basel). 2024 Oct 15;16(20):3490. doi: 10.3390/cancers16203490.
8
Perspectives and Misconceptions of an Online Adult Male Cohort Regarding Prostate Cancer Screening.
Curr Oncol. 2024 Oct 20;31(10):6395-6405. doi: 10.3390/curroncol31100475.
9
Prostate Cancer Among Black Men in Canada.
JAMA Netw Open. 2024 Jun 3;7(6):e2418475. doi: 10.1001/jamanetworkopen.2024.18475.
10
Screening guidelines for individuals at increased risk for prostate cancer.
Can Urol Assoc J. 2024 Oct;18(10):E301-E307. doi: 10.5489/cuaj.8710.
本文引用的文献
1
Evidence-based guideline recommendations on multiparametric magnetic resonance imaging in the diagnosis of clinically significant prostate cancer: A Cancer Care Ontario updated clinical practice guideline.
Can Urol Assoc J. 2022 Feb;16(2):16-23. doi: 10.5489/cuaj.7425.
2
Increase in Prostate Cancer Distant Metastases at Diagnosis in the United States.
JAMA Oncol. 2017 May 1;3(5):705-707. doi: 10.1001/jamaoncol.2016.5465.
3
Extended mortality results for prostate cancer screening in the PLCO trial with median follow-up of 15 years.
Cancer. 2017 Feb 15;123(4):592-599. doi: 10.1002/cncr.30474. Epub 2016 Dec 1.
4
Prostate Health Index improves multivariable risk prediction of aggressive prostate cancer.
BJU Int. 2017 Jul;120(1):61-68. doi: 10.1111/bju.13676. Epub 2016 Nov 22.
5
Properties of the 4-Kallikrein Panel Outside the Diagnostic Gray Zone: Meta-Analysis of Patients with Positive Digital Rectal Examination or Prostate Specific Antigen 10 ng/ml and Above.
J Urol. 2017 Mar;197(3 Pt 1):607-613. doi: 10.1016/j.juro.2016.09.086. Epub 2016 Sep 28.
6
10-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Localized Prostate Cancer.
N Engl J Med. 2016 Oct 13;375(15):1415-1424. doi: 10.1056/NEJMoa1606220. Epub 2016 Sep 14.
7
EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent.
Eur Urol. 2017 Apr;71(4):618-629. doi: 10.1016/j.eururo.2016.08.003. Epub 2016 Aug 25.
8
Baseline Prostate-Specific Antigen Levels in Midlife Predict Lethal Prostate Cancer.
J Clin Oncol. 2016 Aug 10;34(23):2705-11. doi: 10.1200/JCO.2016.66.7527. Epub 2016 Jun 13.
9
Serial Percent Free Prostate Specific Antigen in Combination with Prostate Specific Antigen for Population Based Early Detection of Prostate Cancer.
J Urol. 2016 Aug;196(2):355-60. doi: 10.1016/j.juro.2016.03.011. Epub 2016 Mar 12.
10
The 4Kscore® Test Reduces Prostate Biopsy Rates in Community and Academic Urology Practices.
Rev Urol. 2015;17(4):231-40.
Zotero 插件